Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5205226
Max Phase: Preclinical
Molecular Formula: C31H41N3O5S
Molecular Weight: 567.75
Associated Items:
ID: ALA5205226
Max Phase: Preclinical
Molecular Formula: C31H41N3O5S
Molecular Weight: 567.75
Associated Items:
Canonical SMILES: C=C[C@]1(C)C[C@@H](OC(=O)CSc2nnc(-c3ccc(OC)cc3)[nH]2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
Standard InChI: InChI=1S/C31H41N3O5S/c1-7-29(4)16-23(30(5)18(2)12-14-31(19(3)26(29)37)15-13-22(35)25(30)31)39-24(36)17-40-28-32-27(33-34-28)20-8-10-21(38-6)11-9-20/h7-11,18-19,23,25-26,37H,1,12-17H2,2-6H3,(H,32,33,34)/t18-,19+,23-,25+,26+,29-,30+,31+/m1/s1
Standard InChI Key: SAGMUFGCKUBSCQ-ZIMDNTAOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 567.75 | Molecular Weight (Monoisotopic): 567.2767 | AlogP: 5.48 | #Rotatable Bonds: 7 |
Polar Surface Area: 114.40 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 8.36 | CX Basic pKa: 1.73 | CX LogP: 4.88 | CX LogD: 4.84 |
Aromatic Rings: 2 | Heavy Atoms: 40 | QED Weighted: 0.26 | Np Likeness Score: 0.93 |
1. Wang X, Wang R, Zhang ZS, Zhang GY, Jin Z, Shen R, Du D, Tang YZ.. (2022) Semisynthetic pleuromutilin antimicrobials with therapeutic potential against methicillin-resistant Staphylococcus aureus by targeting 50S ribosomal subunit., 237 [PMID:35430480] [10.1016/j.ejmech.2022.114341] |
Source(1):